Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 9/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | CDK4 | P11802 | 14/20 | 0.44 |
| ▸ | CCND1 | P24385 | 13/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.44 |
| ▸ | CDK2 | P24941 | 7/20 | 0.44 |
| ▸ | CCND2 | P30279 | 5/20 | 0.43 |
| ▸ | CCND3 | P30281 | 5/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.43 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041556 | 0.93 | MAPK8 (0.48) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15035392 | 0.86 | CDK4 (0.47) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15041295 | 0.78 | MAPK8 (0.49) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15034993 | 0.76 | FGFR1 (0.44) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15035294 | 0.75 | MAPK8 (0.55) | FGFR1FGFR2FGFR4FGFR3CDK4 | |
| SCHEMBL15034860 | 0.74 | FGFR1 (0.43) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15035556 | 0.74 | FGFR1 (0.47) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15035409 | 0.73 | MAPK8 (0.54) | FGFR1FGFR2FGFR4FGFR3CDK4 | |
| SCHEMBL15277149 | 0.73 | MAPK8 (0.43) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15035850 | 0.73 | FGFR1 (0.42) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | FGFR1 1919/4885FGFR2 1706/4885FGFR4 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.